Prihlásiť sa Zaregistrujte sa zadarmo

Návratnosť kapitálu spoločnosti AC Immune SA

Aká je hodnota metriky Návratnosť kapitálu spoločnosti AC Immune SA?

Hodnota metriky Návratnosť kapitálu spoločnosti AC Immune SA je -39.43%

Aká je definícia metriky Návratnosť kapitálu?



Return on capital employed (ROCE) je finančný ukazovateľ, ktorý meria rentabilitu spoločnosti a účinnosť spoločnosti vo využívaní vlastného kapitálu.

Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.

ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.

Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.

Návratnosť kapitálu spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou AC Immune SA

Čomu sa venuje spoločnosť AC Immune SA?

ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor

Firmy s metrikou návratnosť kapitálu podobnou spoločnosti AC Immune SA